title: Anti-HER2 therapy in elderly breast cancer patients.
abstract: Targeting anti-HER-2 therapy, trastuzumab, Lapatinib, T-DM1, and Pertuzumab is a standard therapy for HER-2-overexpressing breast cancer. But there are less data available related to anti-HER-2 therapy in elderly patients because they have been consistently underrepresented in clinical trials. Anti- HER-2 therapy among an elderly population was reviewed including approaches for making treatment effective.
authors.affiliation: 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan. m-sawaki@aichi-cc.jp.
authors.forename: Masataka
authors.initials: M
authors.lastname: Sawaki
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism; D004273:DNA, Neoplasm / Q000235:genetics; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000096:biosynthesis / Q000235:genetics; D000068878:Trastuzumab / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D004273:DNA, Neoplasm; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human